Antibody-Drug Conjugates - Is This Help For COVID-19 Treatment? - An Emerging Hint Of Opportunity | Players - ImmunoGen, Seattle Genetics, Roche, Takeda

NOTE: We release the study of the Impact of COVID-19 on the KEYWORD Market which would mention How the COVID-19 is Affecting the KEYWORD Industry, Market Growth Trends and Essential Opportunities in the COVID-19 Landscape, COVID-19 Impact on Key Regions and Proposal for KEYWORD Players to Combat COVID-19 Impact.

The Global Antibody-drug Conjugates Market: 2020 Industry Report is a professional and in-depth study on the current state of the Antibody-drug Conjugates Market by SMI. The Antibody-drug Conjugates market is supposed to demonstrate considerable growth during the forecast period of 2020-2027. The company profiles of all the key players and brands that are dominating the market have been given in this report. Their moves like product launches, joint ventures, mergers and acquisitions and the respective effect on the sales, import, export, revenue, and CAGR values have been studied completely in the report. The scope of this Antibody-drug Conjugates market report can be expanded from market scenarios to comparative pricing between major players. The emerging trends along with major drivers, challenges and opportunities in the market are also identified and analyzed in this report.

Antibody-drug conjugates are class of highly potent biological drugs that combine monoclonal antibodies specific to surface antigens which are present on particular tumor cells with highly potent anti-cancer agents associated with a chemical linker. These drugs are especially used to treat cancer by targeting and killing tumor cells while sparing healthy cells present around. These drugs offer very high specificity to the targeted cells while maximizing their efficacy and minimizing the side-effects associated. Blood cancer, lung cancer, breast cancer, and brain tumor are some of the major application areas of antibody-drug conjugates.

Access insightful study with over 100+ pages, list of tables & figures, profiling 10+ companies. Ask for Sample Copy @ https://www.stratagemmarketinsights.com/sample/11604

Rising prevalence of cancer around the globe due unhealthy lifestyle is expected to propel the market growth of antibody-drug conjugates over the forecast period. According to the World Health Organization, cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Moreover, the rising number of partnerships among major players for developing and commercializing the advanced antibody-drug conjugates is further expected to foster market growth. For instance, in March 2019, AstraZeneca has entered into a development and commercialization collaboration agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for trastuzumab deruxtecan (DS-8201), an antibody-drug conjugate (ADC) and potential new targeted medicine for cancer treatment.

From the geographical perspective, North America is expected to gain significant growth over the forecast period and this can be attributed to the presence of well-established healthcare industry and rising expenditure on healthcare by the government in the region. According to The Centers for Medicare & Medicaid Services, the U.S. health care spending grew 4.6 percent in 2018, reaching $3.6 trillion or $11,172 per person. As a share of the nation's Gross Domestic Product, health spending accounted for 17.7 percent.

The key factors that drive the growth of the market are the high demand for low-cost shipping, the ability to identify customers' needs and respond quickly with logistics solutions. Trends such as the high demand for integrated services further propel market growth. Generally, freight forwarders provide customers with a wide range of integrated services, which not only includes the usual transport of cargo from source to destination, but also a host of other services. Moreover, a rise in trade agreements between nations also helps increase the market growth. However, an increase in reshoring and nearshoring manufacturing hinders the market growth. Irrespective of challenges, the increasing trend of intermodal freight transportation will further boost market growth in the future.

Competitive Analysis:

The report covers major players operating in the Antibody-drug Conjugates market along with the key strategies implemented to achieve a competitive edge against a majority of the vendors which provides a competitive outlook of the industry. The competitive landscape further includes details about different players and their position on a global and a local level is also explained in detail in this compiled study. These insights were prepared through mapping business strategies and products that offer high revenue generation capacities.

Manufacturer Detail:

o ImmunoGen
o Seattle Genetics
o Roche
o Takeda

By the Product Type, the market is primarily segmented into:

o Adcetris
o Kadcyla

By Applications, the market is segmented into:

o Breast Cancer
o Lymphoma

The key strategic developments of the Antibody-drug Conjugates market including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the Antibody-drug Conjugates market on a global and regional basis. The study provides a decisive view on the Antibody-drug Conjugates market by segmenting the market based on product, end-user, and regions. All the segments have been analyzed based on present and future trends and the Antibody-drug Conjugates market is estimated from 2020 to 2027. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa with its further bifurcation into major countries.

Antibody-drug Conjugates Market: Regional Analysis

o North America: USA, Canada, and Mexico, etc.
o Asia-Pacific: China, Japan, Korea, India, and Southeast Asia
o The Middle East and Africa: Saudi Arabia, the UAE, Egypt, Turkey, Nigeria, and South Africa
o Europe: Germany, France, the UK, Russia, and Italy
o South America: Brazil, Argentina, Columbia, etc.

Grab Maximum Discount On Antibody-drug Conjugates Market Research Report [Single User|Multi User|Corporate Users] @ https://www.stratagemmarketinsights.com/discount/11604

Global Antibody-drug Conjugates Market Report includes Detailed TOC points:

1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of Global Antibody-drug Conjugates Market
2 Market Segmentation
3 Market Overview
3.1 Rising Government Initiatives
3.2 Strategic Initiative By Market Players
4 Executive Summaries
5 Premium Insights
6 Regulatory Procedure
7 Global Antibody-drug Conjugates Market, By Type
8 Global Antibody-drug Conjugates Market, by Application
9 Global Antibody-drug Conjugates Market, By Deployment
10 Global Antibody-drug Conjugates Market, By End User
11 Global Antibody-drug Conjugates Market, By Distribution Channel
12 Global Antibody-drug Conjugates Market, Company Landscape
13 Company Profile
13.1 Company Snapshot
13.2 Revenue Analysis
13.3 Company Share Analysis
13.4 Product Portfolio

Customization of this Report: This Antibody-drug Conjugates research report could be customized to the customer's requirements. We will ensure you obtain the report which works for your needs.

New Business Strategies, Challenges & Policies are mentioned in Table of Content, Inquire Now (Kindly Use Your Business/Corporate Email Id) @ https://www.stratagemmarketinsights.com/quiry/11604

Contact us:

Mr. Shah
Stratagem Market Insights
Tel: +1 415 871 0703
Email: sales@stratagemmarketinsights.com
For More Report @ S_Blogs

About Us:

Stratagem Market Insights is a management consulting organization providing market intelligence and consulting services worldwide. We bring the expertise of consultants with a cumulative industry experience of more than 70 years. The firm has been providing quantified B2B research and currently offers services to over 350+ customers worldwide. Our reports cover various end-use industries such as Aerospace and Defense, Agriculture, Food and Beverages, Automotive, Chemicals and Materials, Consumer Goods and Retail, Electronics, Energy, Mining, and Utilities, Pharmaceuticals, Manufacturing and Construction, Services, and Healthcare, and ICT.

This release was published on openPR.